These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15822057)

  • 1. The next generation of diabetic nephropathy therapies: an update.
    Williams ME; Tuttle KR
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):212-22. PubMed ID: 15822057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New potential agents in treating diabetic kidney disease: the fourth act.
    Williams ME
    Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
    Tuttle KR; Anderson PW
    Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agents in development for the treatment of diabetic nephropathy.
    Goh SY; Jasik M; Cooper ME
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):447-63. PubMed ID: 18764722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies of diabetic nephropathy.
    Burney BO; Kalaitzidis RG; Bakris GL
    Curr Opin Nephrol Hypertens; 2009 Mar; 18(2):107-11. PubMed ID: 19434047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for diabetic kidney disease.
    Alicic RZ; Tuttle KR
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):121-33. PubMed ID: 24602462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
    Williams ME
    Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
    Kelly DJ; Zhang Y; Hepper C; Gow RM; Jaworski K; Kemp BE; Wilkinson-Berka JL; Gilbert RE
    Diabetes; 2003 Feb; 52(2):512-8. PubMed ID: 12540629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
    Metz TO; Alderson NL; Thorpe SR; Baynes JW
    Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
    Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R
    FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
    Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
    Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice.
    Meier M; Menne J; Haller H
    Diabetologia; 2009 May; 52(5):765-75. PubMed ID: 19238353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruboxistaurin.
    Taulien CA; Joy SV
    Drugs Today (Barc); 2006 Sep; 42(9):577-85. PubMed ID: 17028667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
    Kelly DJ; Chanty A; Gow RM; Zhang Y; Gilbert RE
    J Am Soc Nephrol; 2005 Jun; 16(6):1654-60. PubMed ID: 15843473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
    Anderson PW; McGill JB; Tuttle KR
    Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):397-402. PubMed ID: 17693752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
    Gilbert RE; Kim SA; Tuttle KR; Bakris GL; Toto RD; McGill JB; Haney DJ; Kelly DJ; Anderson PW
    Diabetes Care; 2007 Apr; 30(4):995-6. PubMed ID: 17229944
    [No Abstract]   [Full Text] [Related]  

  • 18. Ruboxistaurin: LY 333531.
    Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
    Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
    Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase C-beta inhibition for diabetic kidney disease.
    Tuttle KR
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.